Evidence map›Paper›PMID 35284040›Full record

ArticleOncotarget2022

Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients.

Eric R Molina, Letitia K Chim, Salah-Eddine Lamhamedi-Cherradi, Sana Mohiuddin, David McCall, Branko Cuglievan, Sandhya Krishnan, Robert W Porter, Davis R Ingram, Wei-Lien Wang and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Mapping the Single-Cell Differentiation Landscape of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  5. Review
  6. Review
  7. IGF-1R targeting in cancer - does sub-cellular localization matter?Journal of experimental & clinical cancer research : CR · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Eric R MolinaDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Letitia K ChimDepartment of Bioengineering, Rice University, Houston, TX, USA.
Salah-Eddine Lamhamedi-CherradiDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Sana MohiuddinDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
David McCallDivision of Pediatrics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Branko CuglievanDivision of Pediatrics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Sandhya KrishnanDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Robert W PorterDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Davis R IngramDepartment of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Wei-Lien WangDepartment of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Alexander J LazarDepartment of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
David W ScottDepartment of Statistics, Rice University, Houston, TX, USA.
Danh D TruongDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Najat C DawDivision of Pediatrics, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Joseph A LudwigDepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Antonios G MikosDepartment of Bioengineering, Rice University, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USRice University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Training and Dissemination CoreP41EB023833 · NIBIB · UNIV OF MARYLAND, COLLEGE PARK · PI FISHER, JOHN P · 2017 to 2021
$6.2M
Three-dimensional Model of Human Ewing SarcomaR01CA180279 · NCI · RICE UNIVERSITY · PI KASPER, FRED KURTIS, LUDWIG, JOSEPH A · 2014 to 2018
$1.8M
Three-dimensional, mechanically tunable scaffold systems to model osteosarcoma heterogeneity and therapeutic responseF31CA213994 · NCI · RICE UNIVERSITY · PI MOLINA, ERIC RODOLFO · 2016 to 2019
$163k
NCI NIH HHS F31 CA213994NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA180279NIBIB NIH HHS P41 EB023833
6 · The paper itself

Abstract

Osteosarcoma (OS) is a genetically diverse bone cancer that lacks a consistent targetable mutation. Recent studies suggest the IGF/PI3K/mTOR pathway and YAP/TAZ paralogs regulate cell fate and proliferation in response to biomechanical cues within the tumor microenvironment. How this occurs and their implication upon osteosarcoma survival, remains poorly understood. Here, we show that IGF-1R can translocate into the nucleus, where it may act as part of a transcription factor complex. To explore the relationship between YAP/TAZ and total and nuclear phosphorylated IGF-1R (pIGF-1R), we evaluated sequential tumor sections from a 37-patient tissue microarray by confocal microscopy. Next, we examined the relationship between stained markers, clinical disease characteristics, and patient outcomes. The nuclear to cytoplasmic ratios (N:C ratio) of YAP and TAZ strongly correlated with nuclear pIGF-1R (r = 0.522,

Indexed as

Bone NeoplasmsOsteosarcomaAdaptor Proteins, Signal TransducingFemaleHumansPhosphatidylinositol 3-KinasesPlacenta Growth FactorProspective StudiesTOR Serine-Threonine KinasesTranscription FactorsTumor MicroenvironmentAdaptor Proteins, Signal TransducingPhosphatidylinositol 3-KinasesPlacenta Growth FactorTOR Serine-Threonine KinasesTranscription FactorsIGF-1Rmechanotransductionnuclear IGF-1RosteosarcomaYAP/TAZ

Identifiers

PMID35284040
PMCPMC8906536
OpenAlexW4221037582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.